FDA Panel Votes to Ease Rules on Certain Peptides, Including BPC-157

A special committee advising the U.S. Food and Drug Administration voted this week to loosen rules on certain compounds called peptides. The committee said that four peptides — BPC-157, KPV, TB-500, and MOTS-c — should be allowed to be made by compounding pharmacies. However, many FDA scientists strongly disagreed with the decision, saying there is not enough proof that these compounds are safe or effective.

Peptides are small proteins that the body naturally makes. In recent years, they have become very popular in the wellness industry. Supporters claim peptides can help with things like anti-aging, better sleep, and faster healing from injuries. Well-known figures like Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan have spoken positively about them.

Right now, these peptides exist in what experts call a 'gray market.' That means they are not approved drugs, but people can still buy them online from sellers who label them 'for research use only.' This label is a legal workaround that lets companies sell the compounds without saying they are for human use. Kennedy has argued that allowing pharmacies to compound, or specially prepare, these peptides would move people away from risky gray-market products and toward safer ones.

One of the biggest problems the FDA scientists raised was a surprising one: nobody can fully agree on what these peptides actually are, chemically. Without a clear and accepted chemical formula, it is very hard for the FDA to study or evaluate them. 'We've never faced a problem of, "What is it?"' said Russell Wesdyk, an FDA official, during the Thursday meeting.

The committee's votes do not make the peptides approved drugs. Instead, a 'yes' vote means the committee is recommending that the peptides be added to a special list. Compounding pharmacies are allowed to prepare drugs on that list. The FDA itself will still make the final decision through an official rule proposal.

Eight of the panel members were appointed under Kennedy, and six of those eight run clinics that already offer peptides to patients. For BPC-157, KPV, and TB-500, all eight of Kennedy's appointees voted yes. Six members voted no and one person did not vote either way. The vote for MOTS-c was similar, with seven of the new appointees voting yes.

Some committee members who voted yes said they did so to protect patients. Dr. Haleem Mohammed, a doctor at a men's health clinic in Florida that offers peptides, said he voted yes 'for patient safety, you know, the greater good and medical freedom.' He argued that voting no would push people back to the unregulated gray market, which could be more dangerous. David Pope, a pharmacy official from Georgia, said his yes vote was meant 'to put this decision back into the hands of the patient, the physician and the pharmacist.'

Not everyone agreed. Dr. Brian Lee, a professor at the University of Southern California, voted no and worried that the public might wrongly see the committee's approval as a sign that the products work well. He also noted that about 30% of patients who take a fake pill — called a placebo — still report feeling better, which makes it hard to know if a drug is really working. Dr. Elizabeth Rebello, a doctor at MD Anderson Cancer Center in Texas, also voted no, saying she was worried the committee was reacting to popular demand instead of good science.

Some committee members admitted they felt unsure about what they were even voting on. Josh Mailman, a board president at a medical research foundation, said during the KPV discussion, 'I'm voting on something here, but I don't know what that something is. It's kind of like a black box to me.' He voted no. Another member, Dr. Gabriel Alizaidy, voted yes for BPC-157 but said he was 'frankly disappointed at how incomplete the data was.'

The debate over peptides is part of a larger conversation in the United States about health, science, and who gets to decide what is safe. The FDA scientists said that for some peptides, there was simply no data for them to review at all. The final decision on whether compounding pharmacies can make these peptides will come from the FDA later, after it reviews everything and writes an official proposal.